Effect of Blockade of Tumor Necrosis Factor-α with Etanercept on Surgical Wound Healing in SWISS-OF1 Mice

被引:2
|
作者
Iglesias, Estibaliz [2 ]
O'Valle, Francisco [3 ]
Salvatierra, Juan [2 ]
Aneiros-Fernandez, Jose [2 ]
Cantero-Hinojosa, Jesus [2 ]
Hernandez-Cortes, Pedro [1 ]
机构
[1] Univ Hosp Granada, Dept Orthopaed Surg, Granada, Spain
[2] Univ Hosp Granada, Dept Rheumatol, Granada, Spain
[3] Univ Hosp Granada, Dept Pathol, Granada, Spain
关键词
TUMOR NECROSIS FACTOR; ETANERCEPT; WOUND HEALING; RHEUMATOID-ARTHRITIS;
D O I
10.3899/jrheum.081285
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess whether blockade of tumor necrosis factor-alpha (TNF-alpha) influences surgical wound healing in a normal mouse experimental model. Methods. Wound healing time course and degree of surgical wound collagenization were measured by morphological techniques and digital image analysis in 80 male SWISS-OF1 mice (40 received subcutaneous etanercept at a dose of 0.1 mg/25g/at -7, 0, 7, and 14 days). Results. No significant differences were observed between treated and untreated animals in wound healing, re-epithelialization, or formation of inflammatory infiltrate or granulation tissue at days 7, 15, or 20 after surgery. At 20 days, the collagen area was larger in treated versus untreated mice (109029 +/- 28489 mu m(2) vs 79305 +/- 19798 mu m(2), p = 0.026, Mann-Whitney U test). Conclusion. Surgical wounds showed a higher degree of collagenization at 20 days in etanercept-treated versus untreated mice, with no differences in the time course of wound healing. These data suggest that biological therapies to block TNF-alpha do not affect wound healing and do not need to be suspended during the perioperative period. (First Release Sept 1 2009; J Rheumatol 2009;36;2144-8; doi: 10.3899/jrheum.081285)
引用
收藏
页码:2144 / 2148
页数:5
相关论文
共 50 条
  • [21] Pulsating Back Pain Associated with Tumor Necrosis Factor-α Blockade
    Rozin, Alexander P.
    Braun-Moscovici, Yolanda
    Balbir-Gurman, Alexandra
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (12) : 1912 - 1913
  • [22] Tumor necrosis factor-α blockade ameliorates diabetic nephropathy in rats
    Cheng, Dongsheng
    Liang, Rulian
    Huang, Baorui
    Hou, Jiasheng
    Yin, Jianyong
    Zhao, Ting
    Zhou, Lu
    Wu, Rui
    Qian, Youcun
    Wang, Feng
    CLINICAL KIDNEY JOURNAL, 2021, 14 (01) : 301 - 308
  • [23] Topical delivery of 4-hexylresorcinol promotes wound healing via tumor necrosis factor-α suppression
    Ahn, Janghoon
    Kim, Seong-Gon
    Kim, Min-Keun
    Kim, Dae-Won
    Lee, Jang-Ha
    Seok, Hyun
    Choi, Je-Yong
    BURNS, 2016, 42 (07) : 1534 - 1541
  • [24] Transcriptional regulation of tumor necrosis factor-α in keratinocytes mediated by interleukin-1β and tumor necrosis factor-α
    Lisby, S
    Hauser, C
    EXPERIMENTAL DERMATOLOGY, 2002, 11 (06) : 592 - 598
  • [25] Autoamplification of tumor necrosis factor-α -: A potential mechanism for the maintenance of elevated tumor necrosis factor-α in male but not female obese mice
    Neels, JG
    Pandey, M
    Hotamisligil, GS
    Samad, F
    AMERICAN JOURNAL OF PATHOLOGY, 2006, 168 (02): : 435 - 444
  • [26] Inhibitory effect of tetrahydroswertianolin on tumor necrosis factor-α-dependent hepatic apoptosis in mice
    Hase, K
    Xiong, QB
    Basnet, P
    Namba, T
    Kadota, S
    BIOCHEMICAL PHARMACOLOGY, 1999, 57 (12) : 1431 - 1437
  • [27] Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis
    Al-Aly, Ziyad
    Pan, Hui
    Zeringue, Angelique
    Xian, Hong
    Mcdonald, Jay R.
    El-Achkar, Tarek M.
    Eisen, Seth
    TRANSLATIONAL RESEARCH, 2011, 157 (01) : 10 - 18
  • [28] Treatment of rheumatic disease by tumor necrosis factor-α blockade:: Knowns and unknowns
    Trentham, DE
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2001, 7 (02) : 120 - 122
  • [30] Using vaccine responses to plumb the immunologic consequences of tumor necrosis factor blockade with etanercept
    Scheifele, DW
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (07) : 1238 - 1240